Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A review of oncology literature compiled by Giuseppe Curigliano, Division of Medical Oncology, IEO, Milan, Italy
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
E. Perez et al. JCO October 1, 2010 vol. 28 no. 28 4307-4315
IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.
Abstract: The Journal of Clinical Oncology
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YL et al. Lancet. 2010 Aug 28;376(9742):687-97
Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer
Abstract: The Lancet
The Nobel Prize in Physiology or Medicine 2010 was awarded to Robert G. Edwards "for the development of in vitro fertilization"
Read: Early stages of fertilization in vitro of human oocytes matured in vitro Edwards RG et al. Nature. 1969 Feb 15;221(5181):632-5
Birth after the reimplantation of a human embryo. Edwards RG et al. Lancet. 1978 Aug 12;2(8085):366.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.